Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Scientific computing in an AI world.

Science (New York, N.Y.)·2026

Same author

Insights from farming Macrocystis pyrifera offshore: phenotypic analysis, genome-wide association studies, genomic selection.

Heredity·2026

Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026

Same author

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Haematologica·2026

Same author

Right aortic arch and double arch assessed by prenatal echocardiography: a population-based study.

European heart journal·2026

Same author

Feasibility and Acceptability of a Breastfeeding Support Intervention Among Mothers of Infants Under Six Months Old Discharged From Malnutrition Treatment in Kilifi County.

Maternal & child nutrition·2026

Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026

Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026

Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026

Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026

Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026

Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 9, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Blinatumomab in Practice.

Jeffrey Lantz¹, Natalie Pham², Caroline Jones³

¹Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.

Current Hematologic Malignancy Reports

|December 7, 2023

Summary

This summary is machine-generated.

Blinatumomab offers improved survival for B-cell acute lymphoblastic leukemia (ALL), even in frontline treatment. This bispecific T-cell engager (BiTE) therapy requires careful management by a multidisciplinary team to mitigate side effects like cytokine release syndrome and neurotoxicity.

Keywords:

Acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia BiTE, CD19-positive B cells Blinatumomab Blincyto Relapsed/refractory acute lymphoblastic leukemia

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 9, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

Hematologic Oncology
Immunotherapy
Clinical Trial Analysis

Background:

Acute lymphoblastic leukemia (ALL) in adults, particularly B-cell ALL, presents challenging survival outcomes despite intensive treatments.
Novel targeted therapies are crucial for improving efficacy and reducing toxicity in B-cell ALL management.

Purpose of the Study:

To evaluate the effectiveness and safety of blinatumomab in treating B-cell ALL.
To provide guidance on managing blinatumomab therapy, considering its adverse events and administration.

Main Methods:

Systematic review of available data on blinatumomab's efficacy and adverse events in B-cell ALL.
Synthesis of evidence regarding its use in relapsed/refractory and frontline settings.
Guidance development for multidisciplinary team-based administration.

Main Results:

Blinatumomab demonstrates effectiveness in B-cell ALL, with growing evidence supporting its use in frontline therapy.
Potential severe side effects include cytokine release syndrome and neurotoxicity, necessitating vigilant monitoring.
Coordinated care by a multidisciplinary team aids early recognition and intervention for adverse events.

Conclusions:

Blinatumomab is a promising immunotherapy for B-cell ALL, improving survival outcomes.
Safe and effective administration relies on a multidisciplinary approach to manage potential toxicities.
Further research is needed to explore blinatumomab in various treatment lines and community settings.